Viewing nowCombinationBikawons Jeong 5/40 mg
Amlodipine Besylate 6.944mg · Olmesartan Medoxomil 40mg
Tablet · Prescription medication · Combination
Kips Biopharma Co., Ltd.

MFDS item code 201903524 · Approved 2019.05.29 · Insurance code 693202150
Treatment of essential hypertension not controlled by monotherapy
This medication is used for patients with essential hypertension whose blood pressure is not adequately controlled with monotherapy of amlodipine or olmesartan medoxomil. It is to be taken additionally when existing treatments are insufficient to lower blood pressure effectively. Properly controlling blood pressure helps reduce the risk of cardiovascular diseases and maintain a healthy lifestyle.
Take one tablet once daily with water, with or without food. It is recommended that it be taken at the same time each day, if possible (e.g., in the morning). Before starting this medicine, it is recommended that the dose be adjusted using the individual components (amlodipine or olmesartan medoxomil). However, if blood pressure is not controlled with monotherapy with either individual component, switching directly to this medicine may be considered. The maximum dose of this medicine is 10/40 milligrams. The maximum blood pressure-lowering effect occurs within 2 weeks of administration; therefore, adjust the dose at intervals of at least 2 weeks, taking the patient's blood pressure response into account. The recommended doses are as follows: - 5/20 milligrams: For patients whose blood pressure is not adequately controlled with monotherapy with amlodipine 5 milligrams or olmesartan medoxomil 20 milligrams. - 10/20 milligrams: For patients whose blood pressure is not adequately controlled with monotherapy with olmesartan medoxomil 20 milligrams. - 5/40 milligrams: For patients whose blood pressure is not adequately controlled with 5/20 milligrams. - 10/40 milligrams: For patients whose blood pressure is not adequately controlled with 5/40 milligrams. ∘Patients with renal impairment: This medicine has not been studied in patients with renal impairment. However, the maximum dose of olmesartan medoxomil for patients with mild or moderate renal impairment (creatine clearance 20-60mL/min) is 20 milligrams once daily. Use of this medicine is not recommended in patients with moderate to severe renal impairment (e.g., creatinine clearance < 20 mL/min) or in patients undergoing dialysis. Monitoring of potassium and creatinine levels is recommended in patients with moderate renal impairment. ∘Patients with reduced effective intravascular volume: In patients who may have reduced effective intravascular volume (Intravascular volume depletion) (e.g., patients taking diuretics, especially those with renal impairment), it is recommended to start treatment at a low dose while closely monitoring their condition. ∘Patients with hepatic impairment: Use with caution in patients with mild or moderate hepatic impairment. The recommended initial dose of olmesartan medoxomil in patients with moderate hepatic impairment is 10 milligrams once daily, and the maximum dose is 20 milligrams once daily. In patients with hepatic impairment who are already receiving other antihypertensive drugs and/or diuretics, blood pressure and renal function should be closely monitored. This medicine should not be administered to patients with severe hepatic impairment. (See section 2, Patients in whom this medicine must not be administered, under Precautions for Use.) ∘Elderly patients: In general, start treatment at a low dose. When adjusting the dose, consider the patient's renal or cardiac function and comorbidities. In elderly patients, blood pressure should be monitored closely and more frequently.
The safety and efficacy of this medicine have not been established in pediatric patients under 18 years of age.
This medication may cause serious harm to the fetus and newborn when taken during the second and third trimesters of pregnancy; therefore, it should be discontinued immediately upon confirmation of pregnancy. Patients with a history of allergy to this drug's active ingredients or other medications in the same class, as well as pregnant or breastfeeding women, patients with severe liver disease or aortic stenosis, patients with bile duct obstruction, patients on renal dialysis, patients in shock, and certain diabetes patients should not take this medication. Hypotensive patients with insufficient fluid or salt should be closely monitored upon initial administration of this medication as blood pressure may drop excessively. If hypotension occurs, the patient should be laid down, and saline may be administered if necessary. Patients with cardiac or vascular issues should be cautious as rapid dilation of blood vessels may lead to hypotension. Heart failure patients should have their cardiac status monitored carefully when taking this medication, and patients with impaired kidney function need special caution. Patients with liver disease may have slower metabolism of this medication, so careful monitoring is required during administration. Patients may experience side effects such as dizziness, headache, hypotension, swelling, gastrointestinal disturbances, etc., while taking this medication. They should consult healthcare professionals if any abnormal symptoms occur. Particularly, this medication can interact with other drugs, so it is crucial to inform healthcare providers of any other medications being taken, and it is advisable to avoid taking it with grapefruit juice. Use of this medication during pregnancy should be avoided, and it is recommended that if pregnancy is planned or confirmed, a discussion with a physician regarding safe alternative medications be conducted. Breastfeeding women should consider the possibility of this medication being transmitted through breast milk and may need to stop breastfeeding or discontinue its use due to potential side effects in infants. Safety and efficacy have not been established for pediatric patients under 18 years of age. In elderly patients, reduced kidney and liver function may slow drug metabolism, so starting with a lower dose and carefully adjusting dosage is advised. In cases of overdose, blood pressure may drop excessively, and heart rate may increase; immediate medical attention is necessary.
Not everyone experiences these, and they can vary from person to person.
This medication must be stored in a tightly sealed container to avoid exposure to air or moisture. It is essential to maintain the storage temperature between 1 and 30 degrees Celsius.
Pale yellow, round, film-coated tablet
30 tablets/Alu-Alu [10 tablets/Alu-Alu X 3]
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowCombinationAmlodipine Besylate 6.944mg · Olmesartan Medoxomil 40mg
Tablet · Prescription medication · Combination
Kips Biopharma Co., Ltd.
CombinationOlmesartan Medoxomil 20mg · Amlodipine Besylate 6.944mg
Tablet · Prescription medication · Combination
Korea Daiichi Sankyo Co., Ltd.
CombinationOlmesartan Medoxomil 40mg · Amlodipine Besylate 6.944mg
Tablet · Prescription medication · Combination
Korea Daiichi Sankyo Co., Ltd.
CombinationOlmesartan Medoxomil 40mg · Amlodipine Besylate 13.888mg
Tablet · Prescription medication · Combination
Hanmi Daiichi Sankyo Co., Ltd.
Olmesartan Medoxomil · Amlodipine Besylate
Prescription medication · Combination
SYNEX Co., Ltd.
Olmesartan Medoxomil · Amlodipine Besylate
Prescription medication · Combination
Co., Ltd. Sainex
Olmesartan Medoxomil · Amlodipine Besylate
Prescription medication · Combination
SYNEX Co., Ltd.
CombinationAmlodipine Besylate 6.944mg · Olmesartan Medoxomil 40mg
Tablet · Prescription medication · Combination
Huons Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.